# Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease

> **NCT02264288** · PHASE2 · TERMINATED · sponsor: **Celularity Incorporated** · enrollment: 159 (actual)

## Conditions studied

- Peripheral Arterial Disease
- Diabetic Foot

## Interventions

- **BIOLOGICAL:** 3 x 10^6 cells
- **BIOLOGICAL:** 10 x 10^6 cells
- **BIOLOGICAL:** 30 x 10^6 cells
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02264288
- **Lead sponsor:** Celularity Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-23
- **Primary completion:** 2018-02-28
- **Final completion:** 2018-02-28
- **Target enrollment:** 159 (ACTUAL)
- **Why stopped:** Business decision with all subjects completing at least 1 year follow-up
- **Last updated:** 2020-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264288, "Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02264288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*